CMS rebuffed the HHS Office of Inspector General's suggestion that Medicare Part B
claims for compounded drugs identify the firm producing the product, telling the OIG that CMS can stop payments for drugs not produced under FDA requirements but lacks methods to track or identify compounded drug claims.
claims for compounded drugs identify the firm producing the product, telling the OIG that CMS can stop payments for drugs not produced under FDA requirements but lacks methods to track or identify compounded drug claims.
QUOTED FROM HERE
No comments:
Post a Comment